Juno Looks To Move CAR-T To Solid Tumors Via Editas Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal brings Juno access to CRIPSR genomic-editing technology, one of four deals in the past five weeks aimed at keeping the immuno-oncology biotech on the cutting edge.